跳至主要内容
临床试验/NCT01389206
NCT01389206已完成不适用

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Actelion76 个研究点 分布在 1 个国家目标入组 797 人开始时间: 2011年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
797
试验地点
76
主要终点
Patients achieving guideline-recommended treatment

研究概览

简要总结

Knowledge Translation Program for the guidelines and evidence-based management of PAH patients

详细描述

To improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (defined as: 1) improvement of FC III or IV to FC II; 2) improvement of FC II to FC I; or 3) maintaining FC II or I)

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female adults (≥ 18 years of age)
  • Documented diagnosis of PAH (all of the following): i. RHC demonstrating mPAP > 25 mm Hg and PCWP
  • ≤ 15 and PVR > 3 ii. FEV 1 > 50% predicted normal iii. V/Q and/or CT scan excluding the thromboembolic etiology
  • Diagnosis of PAH < 3 years
  • Need for PAH specific treatment
  • Desire to participate and signs an informed consent

排除标准

  • Any of the criteria below:
  • Poor mental function, drug or substance (e.g.,alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study
  • Prior participation in this program
  • Patients with pulmonary hypertension classified as group 2 - 5 Updated Clinical Classification of Pulmonary Hypertension (5th World Symposium on PH Modified Classification of PH)

研究组 & 干预措施

Standard of care

Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.

干预措施: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi (Drug)

结局指标

主要结局

Patients achieving guideline-recommended treatment

时间窗: 3 years

Proportion of patients achieving guideline-recommended treatment

次要结局

  • Patients achieving optimal functional class(3 years)

研究者

发起方
Actelion
申办方类型
Industry
责任方
Sponsor

研究点 (76)

Loading locations...

相似试验